{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:24:24Z","timestamp":1786947864115,"version":"build-2736575974"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The process for initiating a clinical trial is lengthy, expensive, and often involves a large amount of redundant work. There has been a large number of programs, reforms and reviews carried out by regulators, academics, government groups and other stakeholders globally to identify the barriers to and make recommendations for enhancing initiation of clinical trials and improving their efficiency with comparatively little success. This study aimed to identify key initiatives implemented to date and determine the critical factors contributing to their success.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study utilises a scoping review of a wide range of data sources to ascertain what are the key programs undertaken to date to improve clinical trial initiation and to understand the critical success factors of these. Following screening and selection, 27 data sources from 19 relevant programs were included in this review. Sources were included if they were an initiative that had been implemented, in any jurisdiction, to improve the efficiency of the trial initiation process, for medical devices or pharmaceuticals. Included sources were analysed to identify common characteristics, approaches, and determinants of successful implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most initiatives aimed at improving clinical trial efficiency were identified in the United States, despite the issue being global in scope. The majority of programs are regulatory bodies or research groups or a combination of both. Key determinants of success included the stakeholders involved, as well as the resources and approach to increasing efficiency. Programs reporting success attributed this to enthusiastic stakeholders from diverse backgrounds and who had the authority to implement the planned changes. Effective resource utilisation included pooling expertise and infrastructure from large networks, adopting new technologies, and employing dedicated staff. A key aspect of the approach was to create a standardised and centralised system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Efforts to improve clinical trial initiation have predominantly been concentrated in the United States and are commonly driven by collaborative regulatory and research-focused initiatives. Successful programs are characterised by multidisciplinary stakeholder engagement, operational authority, shared resources, technological integration, and centralised standardised systems. These findings may inform the development of future strategies to improve the efficiency of clinical trial initiation globally.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1913657","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:26:33Z","timestamp":1786944393000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Global initiatives to improve clinical investigation efficiency: a scoping review of implemented system-level reforms"],"prefix":"10.3389","volume":"13","author":[{"given":"Ali","family":"McDonnell","sequence":"first","affiliation":[{"name":"School of Medicine, University of Galway","place":["Galway, Ireland"]},{"name":"School of Medicine, Trinity College Dublin","place":["Dublin, Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majella","family":"Geraghty","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Galway","place":["Galway, Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"McDermott","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Galway","place":["Galway, Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Melvin","sequence":"additional","affiliation":[{"name":"Institute for Clinical Trials, University of Galway","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.47176\/mjiri.33.37","article-title":"Challenges in the design, conduct, analysis, and reporting in randomized clinical trial studies: a systematic review","volume":"33","author":"Varse","year":"2019","journal-title":"Med J Islam Repub Iran"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"106505","DOI":"10.1016\/j.cct.2021.106505","article-title":"Development and implementation of standardized study performance metrics for a VA healthcare system clinical research consortium","volume":"108","author":"Johnson","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1136\/neurintsurg-2012-010400","article-title":"The FDA approval process for medical devices: an inherently flawed system or a valuable pathway for innovation?","volume":"5","author":"Fargen","year":"2013","journal-title":"J Neurointerv Surg"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cct.2015.11.011","article-title":"Cost-benefit assessment of using electronic health records data for clinical research versus current practices: contribution of the electronic health Records for Clinical Research (EHR4CR) European project","volume":"46","author":"Beresniak","year":"2016","journal-title":"Contemp Clin Trials"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int J Soc Res Methodol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"Peters","year":"2020","journal-title":"JBI Evid Synth"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138237","article-title":"The role of Google scholar in evidence reviews and its applicability to Grey literature searching","volume":"10","author":"Haddaway","year":"2015","journal-title":"PLoS One"},{"key":"ref9","year":"2023"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12874-025-02528-y","article-title":"Using artificial intelligence for systematic review: the example of elicit","volume":"25","author":"Bernard","year":"2025","journal-title":"BMC Med Res Methodol"},{"key":"ref11","year":""},{"key":"ref12","year":"2022"},{"key":"ref13","year":"2025"},{"key":"ref14","first-page":"867","volume-title":"Centralized Management of Clinical trial Feasibility Requests: A Single Center Database Analysis from 2008 to 2015Clin. Invest.","author":"Arenz","year":"2016"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.18063\/JMDS.2015.02.003","article-title":"New initiatives for transforming clinical research in Korea","volume":"1","author":"Chee","year":"2015","journal-title":"J Med Dev Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jchf.2025.01.011","article-title":"An innovative program for evidence generation: HFC perspective on the FDA Total product life cycle advisory program","volume":"13","author":"Fiuzat","year":"2025","journal-title":"JACC Heart Fail"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/2168479016634148","article-title":"Process innovation improves trial operation efficiency","author":"Choi","year":"2016","journal-title":"Ther Innov Regul Sci"},{"key":"ref18","volume-title":"Operational Efficiency Working Group Clinical Trials Advisory Committee Report","author":"Doroshow","year":"2009"},{"key":"ref19","year":""},{"key":"ref20","year":""},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2018.319","article-title":"A collaborative, academic approach to optimizing the national clinical research infrastructure: the first year of the trial innovation network","author":"Bernard","year":"2018","journal-title":"J Clin Transl Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1017\/S104795111900163X","article-title":"Enhancing efficiency and scientific impact of a clinical trials network: the pediatric heart network integrated CARdiac data and outcomes (iCARD) collaborative","volume":"29","author":"Pasquali","year":"2019","journal-title":"Cardiol Young"},{"key":"ref23","year":"2015"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.14789\/jmj.60.210","article-title":"The future of Cancer clinical trials systems","volume":"60","author":"K","year":"2014","journal-title":"Juntendo Med J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.898","article-title":"Transforming the activation of clinical trials","author":"Watters","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.conctc.2017.03.006","article-title":"A cross-cutting approach to enhancing clinical trial site success: the Department of Veterans Affairs\u2019 network of dedicated enrollment sites (NODES) model","volume":"6","author":"Condon","year":"2017","journal-title":"Contemp Clin Trials Commun"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.109-5199","article-title":"Streamlining the ethics review system","author":"Lough","year":"2016","journal-title":"Can Med Assoc J"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/1740774518755054","article-title":"The clinical trials transformation initiative: methodology supporting the mission","volume":"15","author":"Corneli","year":"2018","journal-title":"Clin Trials (London, England)"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s44222-024-00212-2","article-title":"Digitalizing health trials by the clinical trials transformation initiative","volume":"2","author":"Goldhahn","year":"2024","journal-title":"Nat Rev Bioeng"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4415\/ANN_11_01_04","article-title":"The clinical trials transformation initiative (CTTI)","volume":"47","author":"Grignolo","year":"2011","journal-title":"Ann DellIstituto Super Sanita"},{"key":"ref31","year":"2025"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ijmedinf.2016.11.003","article-title":"Business analysis for a sustainable, multi-stakeholder ecosystem for leveraging the electronic health Records for Clinical Research (EHR4CR) platform in Europe","volume":"97","author":"Dupont","year":"2017","journal-title":"Int J Med Inform"},{"key":"ref33","article-title":"European Commission launches COMBINE pilot to streamline approval of studies involving medicinal products and in vitro diagnostic medical devices","author":"Mulryne","year":"2025","journal-title":"BioSlice"},{"key":"ref34","year":"2024"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.omtm.2019.01.010","article-title":"EU regulatory pathways for ATMPs: standard, accelerated and adaptive pathways to marketing authorisation","volume":"13","author":"Detela","year":"2019","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jvir.2017.12.022","article-title":"New regulatory framework for medical devices in Japan: current regulatory considerations regarding clinical studies","volume":"29","author":"Konishi","year":"2018","journal-title":"J Vasc Interv Radiol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1913657\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:26:35Z","timestamp":1786944395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1913657\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":36,"alternative-id":["10.3389\/fmed.2026.1913657"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1913657","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"1913657"}}